Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589744 | 0.83 | FFAR1 (0.51) | FFAR1 | |
| SCHEMBL3594094 | 0.82 | FFAR1 (0.56) | FFAR4FFAR1KEAP1 | |
| SCHEMBL1448093 | 0.81 | KEAP1 (0.52) | ACLYFFAR4FFAR1KEAP1GPR17 | |
| SCHEMBL316406 | 0.77 | SMN1; SMN2 (0.55) | ACLYFFAR1RXRARXRBRXRG | |
| SCHEMBL1558826 | 0.77 | MET (0.42) | — | |
| SCHEMBL29197998 | 0.76 | MAPT (0.55) | — | |
| SCHEMBL3584403 | 0.76 | KEAP1 (0.63) | FFAR4FFAR1KEAP1 | |
| SCHEMBL1350610 | 0.72 | MCL1 (0.56) | FFAR4FFAR1 | |
| SCHEMBL19294596 | 0.71 | FFAR1 (0.55) | FFAR4FFAR1IDO1KEAP1 | |
| SCHEMBL3584933 | 0.71 | FFAR1 (0.51) | FFAR4FFAR1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| EP-2094646-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | ACLY 1316/4885FFAR4 532/4885FFAR1 324/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | ACLY 2609/4885FFAR4 741/4885FFAR1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.